On May 25, 2016, NanoDimension, a leader in 3D printed electronic components, announced that they have successfully completed laboratory testing of a concept validation of a stem cell 3D bioprinter. It is reported that this test was carried out jointly with Accleta. Headquartered in Haifa, Israel, Accellta has developed a range of proprietary technologies to produce high-quality differentiated cells for media, stem cells, and progenitor cells for drug discovery, regenerative medicine, and related research.
It is understood that this feasibility study was conducted in the second quarter of 2016, confirming the combination of the knowledge and technology of the two companies, and the bio-printing of living stem cells can be achieved using a modified 3D printer.
"Live cell 3D printing is a technology that is playing an important role in medical research, but to maximize its potential, you need to improve print speed, print resolution, cell control, survivability, and cell usability and bio-ink technology. Amit Dror, CEO of Nano Dimension, said: "By combining our high-speed, high-precision inkjet capabilities, Accleta's stem cell suspension technology and the ability to induce differentiation by a team of world-renowned engineers and scientists, we High-precision, high-volume 3D bioprinting is possible."
It is reported that the two companies will consider setting up a new entity for these future solutions, but they do not intend to directly invest large amounts of capital to expand their R&D activities, but prefer to raise funds through this jointly established entity.
Specimen Containers,Medical Urine Container,Standard Stool Container,Pp Urine Stool Container
Yancheng Rongtai Labware Co.,Ltd , https://www.shtestlab.com